HORMONAL AND METABOLIC EFFECTS AND PHARMACOKINETICS OF RECOMBINANT INSULIN-LIKE GROWTH FACTOR-I IN GROWTH-HORMONE RECEPTOR DEFICIENCY LARONSYNDROME

Profound growth failure despite elevated GH levels in GH receptor defi ciency (GHRD) results from reduced insulin-like growth factor-I (IGF-I ) synthesis. Recent reports of improved growth velocity in children wi th GHRD during IGF-I therapy indicate growth-promoting potential in hu mans. We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 mug/kg every 12 h) given sc for 7 days to six adults with GHRD. Hypoglycemia (<2.5 mmol/L) did not occur, an d mean 2 h postprandial insulin levels were reduced. Urinary calcium i ncreased 2-fold (P < 0.01), and serum calcium was unchanged. The mean integrated 24-h GH level was suppressed (6.5 +/- 2.1 to 1 +/- 0.2 mug/ L), as were the number of peaks, area under the curve, and clonidine-s timulated GH release (all P < 0.05). The mean pretreatment IGF-I level (36 +/- 2 mug/L) was 19% of the Ecuadorian control value (190 +/- 15 mug/L), it achieved a peak (253 +/- 11 mug/L) between 2-6 h after IGF- I injection, and at 12 h it was 137 +/- 8 mug/L. There were no signifi cant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabo lic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03). Baseline IGF-II levels were 47% of the control va lue and decreased during IGF-I therapy (273 +/-10 to 178 +/- 9 mug/L; P < 0.01), correlating inversely with IGF-I levels (r = -0.3; P < 0.00 1). Although IGF-binding protein-3 (IGFBP-3) levels were not significa ntly influenced, baseline IGFBP-2 levels (153% of the control) increas ed 45% (P < 0.01). We conclude that IGF-I (40 mug/kg every 12 h) given sc to adults with GHRD is safe; achieves normal levels of IGF-I; redu ces insulin, IGF-II, and GH levels; and increases IGFBP-2 concentratio ns and urinary excretion of calcium.